Bozicevic, Field & Francis LLP
Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapy
Anti-SIRPα antibodies, including multi-specific anti-SIRPα antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRPα and can block the interaction of CD47 on one cell with SIRPα on a phagocytic cell. The subject anti-SIRPα antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRPα antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRPα antibodies.
FORTY SEVEN, INC. The Board of Trustees of the Leland Stanford Junior University
C C A C C A A C A C C C C C C C
C07K C07K A61K C07K C07K A61K A61P C07K A61K C07K C07K C07K C07K C07K C07K C07K
inventional inventional inventional inventional additional additional inventional inventional additional additional additional additional additional additional inventional additional
Jens-Peter Aaron Michael Irving L. Jie
Volkmer Ring Weissman Liu